An observational study in Multiple Sclerosis, sponsored by Fondazione Italiana Sclerosi Multipla. Completed. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2019-10-21.
Sponsored by Fondazione Italiana Sclerosi Multipla · Observational
This is a multicentre observational study which involves 43 of the major Italian centres that treat MS. The duration expected for the study participation of each subject was exclusively the necessary one for the screening visit and execution of the ecocolor-Doppler test, which could have also been executed on the same day.
3,460 studies on the registry are indexed under Multiple Sclerosis; 661 are open to participants now.
This study's enrollment of 1,767 is above the median of 100 across 1,016 observational studies indexed under Multiple Sclerosis.
Browse Multiple Sclerosis studies →Fondazione Italiana Sclerosi Multipla is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Subjects aged 18-55 years, non-gender based, non-sex based.
Group A (MS)
Group B (HC)
The subjects included in this group could be, for example, unrelated relatives or spouses of those affected by MS or other diseases in the study or linked to these by affinity restrictions (such as, the father-in-law with the son-in-law, the husband with his wife's brother, etc.) or accompanying persons or operators of other centres.
Group C (OND)
Group D (ONDi)
Exclusion Criteria:
The presence of acute or chronic disease which are disabling or interfere with the design and objective of the study;
* Age 18-55 years; * Unisex patients diagnosed with MS according to McDonald criteria and successive relapse (38, 39), and subjects with CIS; * Course of the disease: RR-SP-PP-CIS; * Disease duration (starting from diagnosis): from 1 month to 25 years for subjects with RR, SP, and PP; a maximum of 5 years for subjects with CIS; * Not in clinical relapse (at least 30 days after the last clinical relapse); * Subjects treated or non-treated with immunomodulatory and immunosupressive drugs; * Signature of the informed consent.
Procedure: neurological examination, Kurtzke EDSS, Barthel scale, ecocolor-Doppler
* Age 18-55 years; * Absence of significant diseases and lack of familiarity with MS, ie health check-ups (HC); * Signature of the informed consent. The subjects included in this group could be, for example, unrelated relatives or spouses of those affected by MS or other diseases in the study, or linked to these by affinity restrictions (such as, the father-in-law with the son-in-law, the husband with his wife's brother, etc.) or accompanying persons or operators of other centres.
Procedure: medical history, vital signs, ecocolor-Doppler
* Aged 18-55 years; * Subjects with other non-inflammatory neurodegenerative disease (OND), for example Parkinson, ALS, ataxy. * Signature of the informed consent.
Procedure: neurological evaluation, ecocolor-Doppler
* Age 18-55 years; * subjects suffering of other inflammatory neurodegenerative diseases (ONDi), for example optical neuromielitys, ADEM, encephalitis, neuro lupus, neurological complications of systemic autoimmune diseases; * Signature of the informed consent.
Procedure: neurological evaluation, ecocolor-Doppler
For the subjects diagnosed with MS (group A), who did not need to be in a period of clinical relapse of the disease (at least 30 days from the last clinical relapse), the duration and the form of the disease was indicated (CIS, RR, SP or PP). The Investigator has submitted these subjects to a neurological examination which included the standard neurological examination, the Kurtzke EDSS (Kurtzke Expanded Disability Status Scale) comprising the functional systems of Kurtzke and the Barthel scale. After completing the selection phase following the previous examinations, the subjects were directed towards the qualified practitioner for the ecocolor-Doppler examination which was performed in blind.
For the subjects affected by OND and ONDi, as in the groups C and D respectively, the Investigator has performed, beside the anamnesis and the physical examination, a specific neurological evaluation which included the compilation of the Barthel scale for the disability evaluation. After completing the selection phase following the previous examinations, the subjects were directed towards the qualified practitioner for performing the ecocolor-Doppler examination which was performed in blind.
For the healthy subjects (HC) of the group B, the Investigator has solely performed the medical history and a check of the vital signs, reporting the demographic and clinical data of the subjects. After completing the selection phase following the previous examinations, the subjects were directed towards the qualified practitioner for the ecocolor-Doppler examination which was performed in blind.
The presence of CCSVI
The protocol provided that the presence of CCSVI was evaluated according to the Zamboni criteria at local level. Therefore, the ecocolor-Doppler images were sent in a randomized process to a central assessor who performed the first centralized reading. In case of disagreement with the local reading, the same images were to be sent to other two central readers, preserving the anonymity, in order to obtain a final evaluation in regards to the CCSVI presence.
Time frame: 29.12.2010-30.05.2012
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione Italiana Sclerosi Multipla